The commissioned facility has about 7,000 TPA capacity to produce various Esters
Jubilant Ingrevia announced the commissioning of its new Diketene derivatives facility at its manufacturing site in North India at Gajraula, Uttar Pradesh.
The newly commissioned facility marks the entry of Jubilant Ingrevia into the fast-growing Diketene business portfolio. This reiterates Jubilant Ingrevia;s commitment towards growth through its integrated business model, by providing value-added products and innovative solutions to its customers.
The commissioned facility has about 7,000 TPA capacity to produce various Esters (Mono Methyl Acetoacetamide, Methyl Acetoacetate, Ethyl Acetoacetate and Ter-Butyl Acetoacetate). The Company’s long-standing association with leading customers in pharmaceuticals, agrochemicals and other industries and its advanced efforts to get product approval from customers, will help in utilising a major portion of the capacity of this new facility in the coming months. Jubilant Ingrevia undertakes to commission future phases of Diketene derivatives as per plan.
Rajesh Srivastava, CEO and MD, Jubilant Ingrevia said, “It gives me immense pleasure to showcase yet another instance where Jubilant Ingrevia has developed a strong chemistry platform proposition using inhouse R&D and technology transfer backed with high operating excellence and clear strategic direction. The commercial launch of the Diketene facility marks the next stage in the growth of the Company, positioning us closer to our client’s requirements of innovative products and solutions using novel and niche chemistry platforms.”
